Ablynx NV (ABLX.BR)
6.02EUR
6:08am EDT
€0.02 (+0.33%)
€6.00
€6.03
€6.05
€6.00
25,211
138,220
€8.10
€2.77
ABLX.BR
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | €291.03 |
| Shares Outstanding (Mil.): | 48.51 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ABLX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 34.05 | 33.02 |
| EPS (TTM): | -0.65 | -- | -- |
| ROI: | -61.29 | -2.50 | 19.07 |
| ROE: | -63.10 | -3.10 | 20.00 |
BRIEF-Ablynx Q1 net loss EUR 6.7 million
BRUSSELS, May 15 - Ablynx NV : * Q1 net loss EUR 6.7 million * Net cash at end Q1 82.2 million EUR
BRIEF-Ablynx shares suspended pending fundraising result
BRUSSELS, Feb 28 - Ablynx NV : * Shares suspended pending results of fundraising - stock market regulator
BRIEF-Ablynx CEO sees partnering deals this year
BRUSSELS, Feb 27 - Ablynx NV : * CEO says during the coming year, expects important new partnering deals * Says net cash burn well controlled at just EUR21.1 million in 2012 * Says EUR62.8 million in cash at end of 2012
BRIEF-Ablynx enters into cancer deal with UK's Spirogen
BRUSSELS, Feb 25 - Ablynx NV : * Ablynx and Spirogen enter into a research collaboration to evaluate the
Ablynx books success with arthritis drug study
BRUSSELS - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
Ablynx books success with arthritis drug study
BRUSSELS, Feb 13 - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
